Related Insights

How to raise startup funds in a tough market — according to a life science investor


Corporate investors remain key pillars of life sciences and healthcare

Ariana Ognibene, Jonathan Norris

Top life science investment trends for early-stage startups

Ben Johnson

SVB's 2022 healthtech report reveals strong investment opportunity in mental health

Christopher Moniz

Healthcare industry sectors: An overview of 2022

Jonathan Norris

6 legal considerations for life science and healthcare startups

Ben Johnson

About the Author

Julie Betts Ebert is a Managing Director on the National Life Science & Healthcare team at Silicon Valley Bank, covering the Mid-Atlantic and Southeast markets.  Julie provides specialized banking services and debt-financing solutions, as well as advice on strategic growth, to life science companies across all sectors and life stages, from early-stage venture-backed enterprises to late-stage public companies. 

Before joining the commercial banking team, Julie spent several years leading SVB’s Strategic Advisory effort, where she was responsible for managing client engagements and leading execution for advisory projects.

Prior to joining SVB, Julie worked for 10 years at Greenhill & Co LLC, a boutique investment bank, spending time in both their New York and London offices. While at Greenhill, Julie advised both public and private companies on M&A and restructuring transactions. She managed both buy-side and sell-side processes, completed complex corporate valuations, conducted transaction negotiations and provided strategic advice. Julie has broad experience across a range of sectors, with a focus on healthcare.

Before Greenhill, Julie also worked at Prudential Securities in the M&A Group and at J.P. Morgan in the Syndicated Leveraged Finance Group.

Julie received an M.B.A. with honors from Columbia Business School and a B.S. from the McIntire School of Commerce at the University of Virginia with concentration in finance.